- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07603700
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)
Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.
Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.
Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.
Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.
Interventions/Exposures:
- Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
- Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
- Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.
Outcomes:
- Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
- Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.
Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: he xu Dr, doctor
- Numéro de téléphone: +86 153 6611 0045
- E-mail: kilogram@163.com
Lieux d'étude
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210006
- Nanjing First Hospital
-
Contact:
- Interventional Vascular Department Director, doctor
- Numéro de téléphone: +86-25-52271000
- E-mail: kilogram@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age unlimited (reflecting real-world population).
- Symptom duration of acute PE ≤ 14 days.
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
- Able to provide informed consent and complete follow-up.
Exclusion Criteria:
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
- Unable to obtain baseline or follow-up CTPA imaging.
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
|
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
Autres noms:
|
|
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
|
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
Autres noms:
|
|
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
|
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
All-Cause Mortality at 30 Days
Délai: 30 days
|
The percentage of participants who die from any cause within 30 days of enrollment.
|
30 days
|
|
All-Cause Mortality at 90 Days
Délai: 90 days
|
The percentage of participants who die from any cause within 90 days of enrollment.
|
90 days
|
|
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
Délai: 48 hours ± 6 hours
|
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
|
48 hours ± 6 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major Bleeding Events
Délai: 48 hours, 7 days, 30 days, 90 days
|
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
|
48 hours, 7 days, 30 days, 90 days
|
|
Clinical Deterioration
Délai: 48 hours, 7 days
|
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
|
48 hours, 7 days
|
|
6-Minute Walk Test (6MWT) Distance
Délai: 30 days, 90 days
|
Change in walking distance from baseline (estimated) to follow-up.
Minimal Clinically Important Difference (MCID) ≥30 meters.
|
30 days, 90 days
|
|
Post-VTE Functional Status (PVFS) Score
Délai: 30 days, 90 days
|
Assessment of functional limitation due to VTE (Scale 0-5).
|
30 days, 90 days
|
|
Quality of Life (PEmb-QoL)
Délai: 90 days
|
The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
90 days
|
|
Symptomatic PE Recurrence
Délai: 90 days
|
Confirmed recurrent PE via CTPA or V/Q scan.
|
90 days
|
|
ICU Length of Stay
Délai: From ICU admission to ICU discharge, assessed up to 30 days
|
Duration of intensive care unit stay during the index hospitalization
|
From ICU admission to ICU discharge, assessed up to 30 days
|
|
Total Hospital Length of Stay
Délai: From hospital admission to hospital discharge, assessed up to 90 days
|
Duration of index hospitalization from emergency department admission to hospital discharge
|
From hospital admission to hospital discharge, assessed up to 90 days
|
|
Total Medical Costs
Délai: Through 90 days
|
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
|
Through 90 days
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biomarker Improvement (Troponin, BNP, D-Dimer)
Délai: 48 hours, 7 days
|
Percentage reduction in cardiac biomarkers and D-Dimer levels.
|
48 hours, 7 days
|
|
Daily Step Count
Délai: Continuous monitoring through 90 days
|
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period.
Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
|
Continuous monitoring through 90 days
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Maladies des voies respiratoires
- Maladies pulmonaires
- Embolie et thrombose
- Embolie
- Thromboembolie
- Embolie pulmonaire
- Thromboembolie veineuse
- Mécanismes moléculaires d'action pharmacologique
- Agents modulateurs de la fibrine
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Pyridines
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Pyrans
- Actions pharmacologiques
- Actions et utilisations chimiques
- Utilisations thérapeutiques
- Glucides
- Hydrolases
- Enzymes
- Enzymes et coenzymes
- Protéines sanguines
- Héparine, faible poids moléculaire
- Glycosaminoglycanes
- Polysaccharides
- Morpholines
- Oxazines
- Thiophenes
- Coumarines
- Benzopyrans
- Endopeptidases
- Hydrolases peptidiques
- Sérine endopeptidases
- Sérine protéases
- Activateurs de plasminogène
- Facteurs de coagulation sanguine
- Agents cardiovasculaires
- 4-hydroxycoumarines
- Activateur de plasminogène tissulaire
- Agents hématologiques
- Rivaroxaban
- Dabigatran
- Ténectéplase
- Énoxaparine
- Warfarine
- Héparine
- Anticoagulants
- Agents fibrinolytiques
- apixaban
- édoxaban
- Urokinase-Type Plasminogen Activator
Autres numéros d'identification d'étude
- KY20260205-04
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .